Sysmex and QIAGEN have built a successful partnership since the initial collaboration back in 2013 and agreed to expand it to include a strategic alliance for companion diagnostics1 in 2021. As part of the newly expanded collaboration, both companies will further combine their respective products and strengths in genetic testing to deliver high-value products to their global customers.

Sysmex will implement QIAGEN’s assay to be used for clinical trials that QIAGEN provides to pharmaceutical companies and research institutions at Sysmex's global network laboratories (Sysmex Inostics, Inc. CLIA lab2, Sysmex Research and Development Center and Sysmex affiliated company, RIKEN GENESIS Co., Ltd. (HQ: Shinagawa-ku, Tokyo; President and CEO: Kenji Iwakabe) and support QIAGEN's global services. 

For more than 50 years, Sysmex has enhanced its global presence within the in vitro diagnostics field by evolving its genetic testing portfolio. One of the ways is by bringing personalized medicine to patients and healthcare professionals through product development using liquid biopsy3 technology. Sysmex has built a global sales and services network that utilizes its world-class laboratories in Japan and the United States. Sysmex intends to accelerate the creation of high-value testing and develop diagnostic technologies further.

QIAGEN is a pioneer in precision medicine4 and the leader in collaborating with pharmaceutical and biotechnology companies to develop companion diagnostics. These can detect genetic abnormalities to provide insights that guide clinical decision-making about treatments. From polymerase chain reaction (PCR), multiplex PCR, digital PCR (dPCR)5 to next-generation sequencing (NGS)6, QIAGEN offers an unmatched breadth of technologies, which means it can tailor products to the needs of pharmaceutical companies. The company has master collaboration agreements to develop and commercialize companion diagnostics with more than 30 global pharma companies worldwide.